With the aim of understanding the role of CDK12 in tumor growth and response to therapy better, we used CRISPR/Cas9 technology to generate a CDK12 knock-out system in A2780 ovarian cancer cell lines. This evidence concerns the gene CDK12 and ovarian carcinoma.